Abstract 63P
Background
Melatonin (MT) regulates sleep and antioxidants while interacting with our microbiota. Advances in technology allow a deeper understanding of our microbiome and its environment. Research is now focused on plant-derived molecules, including sulforaphane (SFN), known for activating antioxidant responses through the Nrf2 pathway and inhibiting NF-κB. This knowledge paves the way for new research and potential treatment strategies, highlighting the potential of plant-derived molecules.
Methods
Our study observed decreased melatonin levels in 52 cancer patients with severe dysbiosis. This group also had reduced Lactobacillus acidophilus and saccharomyces boulardii. By culturing these microorganisms and adding melatonin, we saw an enhanced expression of the myrosinase gene (TGG1), and strong antiproliferative effects on cancer cultures. Our findings highlight melatonin's potential role in modulating microorganism behavior and managing dysbiosis in cancer patients.
Results
Our study found low melatonin (MT) levels in cancer patients, linked to decreased Lactobacillus acidophilus and saccharomyces boulardii levels. MT exposure enhanced myrosinase gene expression and showed antiproliferative effects on cancer cultures. The use of NO synthase inhibitor reduced SFN yield, yet MT counteracted this effect. This emphasizes MT's potential role in SFN synthesis regulation and cancer disease initiation. Particularly, in cancer patients, decreased SFN biosynthesis due to deficiency of these microorganisms and dysbiosis may increase oxidative stress, initiating cancerous conditions.
Conclusions
This finding has implications for understanding SFN synthesis regulation by NO and H2O2. Importantly, in cancer patients with a lack of Lactobacillus acidophilus and saccharomyces boulardii and MT deficiency, there's an increased risk of oxidative stress, creating conditions conducive to cancer. Unresolved is whether MT deficiency precedes the failure of these microorganisms and myrosinase gene inhibition, or if these conditions result from deep dysbiosis leading to MT deficiency.
Editorial acknowledgement
Thanks so much of our consultants from Tbilisi State Medical University:
Professor Gaiane Simonia and Professor Nana Okrostsvaridze
Clinical trial identification
Legal entity responsible for the study
Tbilisi State Medical University and Institute for Personalized Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract